Fibromyalgia syndrome

Philip J. Mease, Lesley M. Arnold, Robert (Rob) Bennett, Annelies Boonen, Dan Buskila, Serena Carville, Amy Chappell, Ernest Choy, Daniel Clauw, Dina Dadabhoy, Michael Gendreau, Don Goldenberg, Geoffrey Littlejohn, Susan Martin, Philip Perera, I. Jon Russell, Lee Simon, Michael Spaeth, David Williams, Leslie Crofford

    Research output: Contribution to journalArticle

    167 Citations (Scopus)

    Abstract

    The fibromyalgia syndrome (FM) workshop at OMERACT 8 continued the work initiated in the first FM workshop at OMERACT 7 in 2004. The principal objectives were to work toward consensus on core domains for assessment in FM studies, evaluate the performance quality of outcome measures used in a review of recent trials in FM, and discuss the research agenda of the FM working group. An initiative to include the patient perspective on identification and prioritization of domains, consisting of focus groups and a patient Delphi exercise, was completed prior to OMERACT 8. Patient-identified domains were, for the most part, similar to those identified by clinician-investigators in terms of symptoms and relative importance. However, patients identified certain domains, such as stiffness, that were not included by physicians, and emphasized the importance of domains such as dyscognition and impaired motivation. Many of the principal domains agreed upon by the clinician-investigators, patients, and OMERACT participants, including pain, fatigue, sleep, mood, and global measures, have been used in clinical trials and performed well when viewed through the OMERACT filter. The research agenda items reviewed and approved for continued study included development of objective "biomarkers" in FM, development of a responder index for FM, and coordination with the WHO's International Classification of Functioning Disability and Health (ICF) Research Branch and the US National Institutes of Health's Patient Reported Outcome Measures Information System network (PROMIS) to develop improved measures of function, quality of life, and participation. The OMERACT process has provided a framework for identification of key domains to be assessed and a path toward validation and standardization of outcome measures for clinical trials in FM.

    Original languageEnglish (US)
    Pages (from-to)1415-1425
    Number of pages11
    JournalJournal of Rheumatology
    Volume34
    Issue number6
    StatePublished - Jun 2007

    Fingerprint

    Fibromyalgia
    Research
    Research Personnel
    Outcome Assessment (Health Care)
    Clinical Trials
    International Classification of Functioning, Disability and Health
    Education
    Information Services
    National Institutes of Health (U.S.)
    Focus Groups
    Information Systems
    Fatigue
    Motivation
    Consensus
    Sleep
    Biomarkers
    Quality of Life
    Exercise
    Physicians
    Pain

    Keywords

    • Fibromyalgia
    • Omeract
    • Outcome measures
    • Pain

    ASJC Scopus subject areas

    • Rheumatology
    • Immunology

    Cite this

    Mease, P. J., Arnold, L. M., Bennett, R. R., Boonen, A., Buskila, D., Carville, S., ... Crofford, L. (2007). Fibromyalgia syndrome. Journal of Rheumatology, 34(6), 1415-1425.

    Fibromyalgia syndrome. / Mease, Philip J.; Arnold, Lesley M.; Bennett, Robert (Rob); Boonen, Annelies; Buskila, Dan; Carville, Serena; Chappell, Amy; Choy, Ernest; Clauw, Daniel; Dadabhoy, Dina; Gendreau, Michael; Goldenberg, Don; Littlejohn, Geoffrey; Martin, Susan; Perera, Philip; Russell, I. Jon; Simon, Lee; Spaeth, Michael; Williams, David; Crofford, Leslie.

    In: Journal of Rheumatology, Vol. 34, No. 6, 06.2007, p. 1415-1425.

    Research output: Contribution to journalArticle

    Mease, PJ, Arnold, LM, Bennett, RR, Boonen, A, Buskila, D, Carville, S, Chappell, A, Choy, E, Clauw, D, Dadabhoy, D, Gendreau, M, Goldenberg, D, Littlejohn, G, Martin, S, Perera, P, Russell, IJ, Simon, L, Spaeth, M, Williams, D & Crofford, L 2007, 'Fibromyalgia syndrome', Journal of Rheumatology, vol. 34, no. 6, pp. 1415-1425.
    Mease PJ, Arnold LM, Bennett RR, Boonen A, Buskila D, Carville S et al. Fibromyalgia syndrome. Journal of Rheumatology. 2007 Jun;34(6):1415-1425.
    Mease, Philip J. ; Arnold, Lesley M. ; Bennett, Robert (Rob) ; Boonen, Annelies ; Buskila, Dan ; Carville, Serena ; Chappell, Amy ; Choy, Ernest ; Clauw, Daniel ; Dadabhoy, Dina ; Gendreau, Michael ; Goldenberg, Don ; Littlejohn, Geoffrey ; Martin, Susan ; Perera, Philip ; Russell, I. Jon ; Simon, Lee ; Spaeth, Michael ; Williams, David ; Crofford, Leslie. / Fibromyalgia syndrome. In: Journal of Rheumatology. 2007 ; Vol. 34, No. 6. pp. 1415-1425.
    @article{9b64d391d9e749d183be59f53a11ec26,
    title = "Fibromyalgia syndrome",
    abstract = "The fibromyalgia syndrome (FM) workshop at OMERACT 8 continued the work initiated in the first FM workshop at OMERACT 7 in 2004. The principal objectives were to work toward consensus on core domains for assessment in FM studies, evaluate the performance quality of outcome measures used in a review of recent trials in FM, and discuss the research agenda of the FM working group. An initiative to include the patient perspective on identification and prioritization of domains, consisting of focus groups and a patient Delphi exercise, was completed prior to OMERACT 8. Patient-identified domains were, for the most part, similar to those identified by clinician-investigators in terms of symptoms and relative importance. However, patients identified certain domains, such as stiffness, that were not included by physicians, and emphasized the importance of domains such as dyscognition and impaired motivation. Many of the principal domains agreed upon by the clinician-investigators, patients, and OMERACT participants, including pain, fatigue, sleep, mood, and global measures, have been used in clinical trials and performed well when viewed through the OMERACT filter. The research agenda items reviewed and approved for continued study included development of objective {"}biomarkers{"} in FM, development of a responder index for FM, and coordination with the WHO's International Classification of Functioning Disability and Health (ICF) Research Branch and the US National Institutes of Health's Patient Reported Outcome Measures Information System network (PROMIS) to develop improved measures of function, quality of life, and participation. The OMERACT process has provided a framework for identification of key domains to be assessed and a path toward validation and standardization of outcome measures for clinical trials in FM.",
    keywords = "Fibromyalgia, Omeract, Outcome measures, Pain",
    author = "Mease, {Philip J.} and Arnold, {Lesley M.} and Bennett, {Robert (Rob)} and Annelies Boonen and Dan Buskila and Serena Carville and Amy Chappell and Ernest Choy and Daniel Clauw and Dina Dadabhoy and Michael Gendreau and Don Goldenberg and Geoffrey Littlejohn and Susan Martin and Philip Perera and Russell, {I. Jon} and Lee Simon and Michael Spaeth and David Williams and Leslie Crofford",
    year = "2007",
    month = "6",
    language = "English (US)",
    volume = "34",
    pages = "1415--1425",
    journal = "Journal of Rheumatology",
    issn = "0315-162X",
    publisher = "Journal of Rheumatology",
    number = "6",

    }

    TY - JOUR

    T1 - Fibromyalgia syndrome

    AU - Mease, Philip J.

    AU - Arnold, Lesley M.

    AU - Bennett, Robert (Rob)

    AU - Boonen, Annelies

    AU - Buskila, Dan

    AU - Carville, Serena

    AU - Chappell, Amy

    AU - Choy, Ernest

    AU - Clauw, Daniel

    AU - Dadabhoy, Dina

    AU - Gendreau, Michael

    AU - Goldenberg, Don

    AU - Littlejohn, Geoffrey

    AU - Martin, Susan

    AU - Perera, Philip

    AU - Russell, I. Jon

    AU - Simon, Lee

    AU - Spaeth, Michael

    AU - Williams, David

    AU - Crofford, Leslie

    PY - 2007/6

    Y1 - 2007/6

    N2 - The fibromyalgia syndrome (FM) workshop at OMERACT 8 continued the work initiated in the first FM workshop at OMERACT 7 in 2004. The principal objectives were to work toward consensus on core domains for assessment in FM studies, evaluate the performance quality of outcome measures used in a review of recent trials in FM, and discuss the research agenda of the FM working group. An initiative to include the patient perspective on identification and prioritization of domains, consisting of focus groups and a patient Delphi exercise, was completed prior to OMERACT 8. Patient-identified domains were, for the most part, similar to those identified by clinician-investigators in terms of symptoms and relative importance. However, patients identified certain domains, such as stiffness, that were not included by physicians, and emphasized the importance of domains such as dyscognition and impaired motivation. Many of the principal domains agreed upon by the clinician-investigators, patients, and OMERACT participants, including pain, fatigue, sleep, mood, and global measures, have been used in clinical trials and performed well when viewed through the OMERACT filter. The research agenda items reviewed and approved for continued study included development of objective "biomarkers" in FM, development of a responder index for FM, and coordination with the WHO's International Classification of Functioning Disability and Health (ICF) Research Branch and the US National Institutes of Health's Patient Reported Outcome Measures Information System network (PROMIS) to develop improved measures of function, quality of life, and participation. The OMERACT process has provided a framework for identification of key domains to be assessed and a path toward validation and standardization of outcome measures for clinical trials in FM.

    AB - The fibromyalgia syndrome (FM) workshop at OMERACT 8 continued the work initiated in the first FM workshop at OMERACT 7 in 2004. The principal objectives were to work toward consensus on core domains for assessment in FM studies, evaluate the performance quality of outcome measures used in a review of recent trials in FM, and discuss the research agenda of the FM working group. An initiative to include the patient perspective on identification and prioritization of domains, consisting of focus groups and a patient Delphi exercise, was completed prior to OMERACT 8. Patient-identified domains were, for the most part, similar to those identified by clinician-investigators in terms of symptoms and relative importance. However, patients identified certain domains, such as stiffness, that were not included by physicians, and emphasized the importance of domains such as dyscognition and impaired motivation. Many of the principal domains agreed upon by the clinician-investigators, patients, and OMERACT participants, including pain, fatigue, sleep, mood, and global measures, have been used in clinical trials and performed well when viewed through the OMERACT filter. The research agenda items reviewed and approved for continued study included development of objective "biomarkers" in FM, development of a responder index for FM, and coordination with the WHO's International Classification of Functioning Disability and Health (ICF) Research Branch and the US National Institutes of Health's Patient Reported Outcome Measures Information System network (PROMIS) to develop improved measures of function, quality of life, and participation. The OMERACT process has provided a framework for identification of key domains to be assessed and a path toward validation and standardization of outcome measures for clinical trials in FM.

    KW - Fibromyalgia

    KW - Omeract

    KW - Outcome measures

    KW - Pain

    UR - http://www.scopus.com/inward/record.url?scp=34250176930&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=34250176930&partnerID=8YFLogxK

    M3 - Article

    VL - 34

    SP - 1415

    EP - 1425

    JO - Journal of Rheumatology

    JF - Journal of Rheumatology

    SN - 0315-162X

    IS - 6

    ER -